Nystatin leadership Antibiotice is the world leader in producing the active pharmaceutical ingredient Nystatin, with USP recognition since 2017, presenting a strong competitive moat for antifungal product supply and potential co-development of related therapies.

Global footprint Active presence in Romania and over 70 countries offers multiple regional entry points for partnerships, distribution agreements, and contract manufacturing opportunities to scale generic portfolios and API supply.

Funding momentum Recent multi-million euro/USD financing and a forthcoming €67–77 million funding infusion from Banca Transilvania alongside EIB advisory support indicate strong near-term investment in R&D, manufacturing modernization, and critical medicines development.

R&D expansion Significant planned investment in a new R&D center focused on critical medicines positions Antibiotice for early-stage collaboration, accelerated development programs, and potential co-licensing of innovative generics or specialty formulations.

Quality and compliance EU-GMP, COS, and FDA compliance credentials support FDA/EU market entry and risk-managed supply opportunities, making Antibiotice a credible partner for regional tenders, hospital contracts, and API supply for multinational buyers.